For over a century, scientists and clinicians have collectively combatted cancer using a diversity of approaches, including drug treatment, surgery, radiation and chemotherapy. In spite of the advances in prognosis and therapeutics in different types of cancer, many malignancies including liver, gastric, colorectal, head/neck, breast, ovarian and lung cancers remain difficult to treat.
The long-term objective of the Centre for Oncology and Immunology is to employ novel functional screens, animal and cell models including organoids, immune-oncology approach, as well as advanced genomic and proteomic techniques down to single cell resolution to identify novel “druggable” cancer targets for hard-to-treat malignancies. The ultimate goal is to develop therapeutics against these targets and to conduct clinical trials evaluating these drugs along with biomarkers with an eye to their eventual commercialization worldwide. Success in this venture will address pressing unmet medical needs and establish Hong Kong as a leading hub of innovative anti-cancer and immuno-oncology drug development.